glp-1 startups Riding the Wegovy wave: The shifting focus to GLP-1s to tap the $150bn weight loss drug market How to adapt to the

Even our Gen Z and millenials also are conditioned to be over cautious on these things since childhood

Patients drawing up small doses from highly concentrated vials often struggle with precision

In summary, recent CV outcomes trials with GLP-1RAs have shown promising benefits in CV care of T2D patients, and GLP-1RAs have been accordingly listed as a second line therapy in T2D patients with established atherosclerotic CV disease, alongside SGLT2 inhibitors [5, 6]

Both medications have shown significant results in clinical trials, but the timeline and extent of weight loss can vary between the two

and F.L.R

Michael Schemann for use of his figures, the reviewers and also Dr